51 Brecher M, Rak I, Melvin K, Jones A. The long-term effect of quetiapine (Seroquel) monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract 2000; 4:287-291.
52 Parraga HC, Parraga MI, Woodward RL, Fenning PA. Quetiapine treatment of children with Tourette's syndrome: report of two cases. J Child Adolesc Psychopharmacol 2001; 11:187-191.
53 Shaw JA, Lewis JE, Pascal S, , et al. A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 2001; 11:415-424.
54 Croarkin P, Rayner T. Acute neutropenia in a patient treated with quetiapine. Psychosomatics 2001; 42:368.
55 Ruhe HG, Becker HE, Jessurun P, , et al. Agranulocytosis and granulocytopenia associated with quetiapine. Acta Psychiatr Scand 2001; 104:311-313.
56 Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346:16-22.
57 Hellings JA, Zarcone JR, Crandall K, , et al. Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol 2001; 11:229-238.
58 Martin A, Landau J, Leebens P, , et al. Risperidone-associated weight gain in children and adolescents: a retrospective chart review. J Child Adolesc Psychopharmacol 2000; 10:259-268.
59 Markianos M, Hatzimanolis J, Lykouras L. Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol. Eur Arch Psychiatry Clin Neurosci 2001; 251:141-146.
60 Pezawas L, Quiner S, Moertl D, , et al. Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance. Int Clin Psychopharmacol 2000; 15:207-214.
61 Glassman AH, Bigger JT, Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158:1774-1782.
62 Haverkamp W, Breithardt G, Camm AJ, , et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J 2002; 21:1216-1231.